External Source

Metalmark: Amivantamab And Capmatinib In Advanced Nsclc

2024 1:05
Synopsis
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, discusses the Phase I/II METalmark study (NCT05488314) of ...

You Might Also Like

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC 5:18
Expert Video Report On Amivantamab In Combination Therapy Fo...
2023
MARIPOSA: resistance mechanisms of amivantamab & lazertinib in NSCLC 3:12
Mariposa: Resistance Mechanisms Of Amivantamab & Lazertinib ...
2025
Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC 3:17
Phase Iii Mariposa: Amivantamab + Lazertinib Vs Osimertinib ...
2023
CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC 2:47
Chrysalis-2: Met Ihc As A Biomarker For Amivantamab-lazertin...
2025
FDA Approves Capmatinib for Advanced Lung Cancer 0:46
Fda Approves Capmatinib For Advanced Lung Cancer
2020
Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutation 3:01
Update From Chrysalis: Amivantamab In Patients With Nsclc Wi...
2022
The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC 0:56
The Clinical Impact Of Amivantamab And Chemotherapy In Egfrm...
2024
MARIPOSA - Combination of Amivantamab & Lazertinib for Common EGFR Mutations in NSCLC 20:46
Mariposa - Combination Of Amivantamab & Lazertinib For Commo...
2025
Amivantamab + Lazertinib Administration Method May Affect Outcomes in Advanced NSCLC 4:56
Amivantamab + Lazertinib Administration Method May Affect Ou...
2024
Amivantamab for NSCLC with MET Exon 14 skipping mutations 1:18
Amivantamab For Nsclc With Met Exon 14 Skipping Mutations
2021
Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung Cancer 4:45
Amivantamab And Mobocertinib: Side Effects And Treatment Tim...
2023
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.